首页> 外文期刊>Biomaterials >The effect of stromal cell-derived factor-1α/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration
【24h】

The effect of stromal cell-derived factor-1α/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration

机译:基质细胞衍生因子-1α/肝素涂层可生物降解的血管移植物对内皮细胞和平滑肌祖细胞募集以促进再生的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Small-diameter synthetic vascular grafts have high failure rate and tissue-engineered blood vessels are limited by the scalability. Here we engineered bioactive materials for in situ vascular tissue engineering, which recruits two types of endogenous progenitor cells for the regeneration of blood vessels. Heparin was conjugated to microfibrous vascular grafts to suppress thrombogenic responses, and stromal cell-derived factor-1α (SDF-1α) was immobilized onto heparin to recruit endogenous progenitor cells. Heparin-bound SDF-1α was more stable than adsorbed SDF-1α under both static and flow conditions. Microfibrous grafts were implanted in rats by anastomosis to test the functional performance. Heparin coating improved the short-term patency, and immobilized SDF-1α further improved the long-term patency. SDF-1α effectively recruited endothelial progenitor cells (EPCs) to the luminal surface of the grafts, which differentiated into endothelial cells (ECs) and accelerated endothelialization. More interestingly, SDF-1α increased the recruitment of smooth muscle progenitor cells (SMPCs) to the grafts, and SMPCs differentiated into smooth muscle cells (SMCs) in vivo and in vitro. Consistently, SDF-1α-immobilized grafts had significantly higher elastic modulus. This work demonstrates the feasibility of simultaneously recruiting progenitor cells of ECs and SMCs for in situ blood vessel regeneration. This in situ tissue engineering approach will have broad applications in regenerative medicine.
机译:小直径的合成血管移植物失败率高,而组织工程化的血管受到可扩展性的限制。在这里,我们设计了用于原位血管组织工程的生物活性材料,该材料吸收了两种类型的内源性祖细胞用于血管再生。将肝素与微纤维血管移植物结合以抑制血栓形成反应,并将基质细胞衍生因子-1α(SDF-1α)固定在肝素上以募集内源性祖细胞。在静态和流动条件下,结合肝素的SDF-1α均比吸附的SDF-1α稳定。通过吻合术将微纤维移植物植入大鼠体内以测试其功能。肝素涂层改善了短期通畅性,固定化SDF-1α进一步改善了长期通畅性。 SDF-1α有效地将内皮祖细胞(EPC)募集到移植物的腔表面,然后分化为内皮细胞(EC)并加速了内皮化。更有趣的是,SDF-1α增加了平滑肌祖细胞(SMPC)向移植物的募集,并且SMPC在体内和体外分化为平滑肌细胞(SMC)。一致地,固定有SDF-1α的移植物具有明显更高的弹性模量。这项工作证明了同时募集ECs和SMCs祖细胞用于原位血管再生的可行性。这种原位组织工程方法将在再生医学中具有广泛的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号